Zobrazeno 1 - 10
of 226
pro vyhledávání: '"Anna Balato"'
Autor:
Mario Valenti, Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Diego Orsini, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1649-1657 (2024)
Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safet
Externí odkaz:
https://doaj.org/article/2457ce851f3b4d589b890cf51ca53d3c
Autor:
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Pina Brianti, Giovanna Brunasso, Martina Burlando, Anna E. Cagni, Marzia Caproni, Carlo G. Carrera, Andrea Carugno, Francesco Caudullo, Aldo Cuccia, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Paolo Gisondi, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Maria L. Musumeci, Diego Orsini, Simone Ribero, Valentina Ruffo Di Calabria, Francesca Satolli, Davide Strippoli, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractPurpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildra
Externí odkaz:
https://doaj.org/article/50011e4f4d42477e96cf16f9d602b59b
Autor:
Elvira Moscarella, Andrea Ronchi, Camila Scharf, Giulia Briatico, Vittorio Tancredi, Caterina Longo, Anna Balato, Giuseppe Argenziano
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 3 (2024)
Externí odkaz:
https://doaj.org/article/dac72a9d3f27438184ed7ed40eba018e
Autor:
Giulia Briatico, Gabriella Brancaccio, Camila Scharf, Elvira Moscarella, Eugenia Veronica Di Brizzi, Anna Balato, Giuseppe Argenziano
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 3 (2024)
Externí odkaz:
https://doaj.org/article/dac64e9e429d40a79b927a3a2e33df06
Autor:
Paolo Dapavo, Gabriella Fabbrocini, Elena Campione, Claudia Giofrè, Anna Balato, Concetta Potenza, Stefano Dastoli, Piergiorgio Malagoli, Annamaria Offidani, Federico Bardazzi, Ketty Peris, Paolo Pella, Rocco De Pasquale, Claudio Bonifati, Alfredo Giacchetti, Sabatino Pallotta, Maurizio Congedo, Paolo Amerio, Maria Concetta Fargnoli, Piergiacomo Calzavara Pinton, Marina Venturini, the BRIGHT Study Group
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 4, Pp 739-752 (2023)
Abstract Background Brodalumab, a fully human anti‐interleukin (IL)‐17 monoclonal antibody that blocks IL‐17RA, is approved in Europe for the treatment of adult patients with moderate‐to‐severe plaque psoriasis who are candidates for system
Externí odkaz:
https://doaj.org/article/32e63bc3aabf482aa696331c742f6d4b
Autor:
Anna Balato, Francesca Ambrogio, Martina Burlando, Carlo Giovanni Carrera, Andrea Chiricozzi, Maria Esposito, Stefano Piaserico, Miriam Teoli, Paolo Gisondi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 1, Pp 5-13 (2023)
Externí odkaz:
https://doaj.org/article/47d2afcf1e714ff893cbd91f46ffd377
Autor:
Diego Orsini, Piergiorgio Malagoli, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Valentina Dini, Maria Esposito, Maria C. Fargnoli, Francesca M. Gaiani, Luigi Gargiulo, Paolo Gisondi, Alessandro Giunta, Luciano Ibba, Claudia Lasagni, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Alessandra Narcisi, Annamaria Offidani, Giovanni Paolino, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Chiara Assorgi, Antonio Costanzo
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 2 (2024)
Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis,
Externí odkaz:
https://doaj.org/article/59fd209fd8eb441cabd179657001da3a
Autor:
Paola Secchiero, Erika Rimondi, Annalisa Marcuzzi, Giovanna Longo, Chiara Papi, Marta Manfredini, Matteo Fields, Lorenzo Caruso, Roberta Di Caprio, Anna Balato
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 15, p 8098 (2024)
In recent years, the incidence of metabolic syndrome (MS) has increased due to lifestyle-related factors in developed countries. MS represents a group of conditions that increase the risk of diabetes, cardiovascular diseases, and other severe health
Externí odkaz:
https://doaj.org/article/0c960896e5ab4f5591a29d72c8d42683
Autor:
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionThe development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives of patients. Despite the wide use of interleukin (IL) inhibitors, limited data are available to date regardin
Externí odkaz:
https://doaj.org/article/e8adfd5931624f3f9e09c85cb9c18c40
Autor:
Stefano Dastoli, Maria Passante, Francesco Loconsole, Edoardo Mortato, Anna Balato, Vincenzo Piccolo, Claudio Guarneri, Laura Macca, Eugenio Provenzano, Giancarlo Valenti, Domenico D’Amico, Giuseppe Micali, Maria Letizia Musumeci, Giovanni Palazzo, Caterina Foti, Paolo Romita, Gabriella Fabbrocini, Matteo Megna, Ilaria Sammarra, Luigi Bennardo, Cataldo Patruno
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Long-term real-life data on secukinumab use in psoriasis are limited. Objectives Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in real-life. Methods Multicenter retrospective study analyzing data from
Externí odkaz:
https://doaj.org/article/4fa564bfcdbe423d8500634beff35987